GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Chengdu Kanghua Biological Products Co 300841.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

50.12

-1.84%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Chengdu Kanghua Biological Products Co

Its shares trade on Shenzhen under the ticker 300841.SZ. It has been listed since 16 June 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.17bn and net income of CN¥219.9m. At that date it held total assets of CN¥4.01bn and shareholders' equity of CN¥3.54bn.

Chengdu Kanghua Biological Products Co., Ltd. engages in the production and sale of preventive biological products. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2020-06-16. The firm's main products are Rabies Vaccine (human diploid cell) for Human Use, Freeze-dried and Group ACYW135 Meningococcal Polysaccharide Vaccine. The firm distributes its products in domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
16 Jun 2020
Employees
673
Website
kangh.com ↗

Leadership

Pay as last reported

  • Mr. Zhentao WangChairman of the Board, since 2023CN¥720,000
  • Mr. Hongbo WuPresident, Director, since 2023
  • Mr. Wennian WuFinance Director, Deputy General Manager, Secretary of the Board, Director
  • Mr. Fu WangVice President
  • Mr. Huaigong ChenDeputy General Manager, Quality ManagerCN¥1.1m
  • Mr. Shengyou LiDeputy General ManagerCN¥1.0m
  • Mr. Jun LiuDirector
  • Mr. Xiongping YuDirectorCN¥96,000
  • Mr. Xiaobo FangIndependent DirectorCN¥96,000
  • Ms. Haiying TaoIndependent DirectorCN¥44,100
  • Mr. Binghui ZhangIndependent DirectorCN¥96,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Produces Rabies Vaccine (human diploid cell) for Human Use
  • Distributes products domestically and overseas
  • Has 673 full-time employees

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No financial data provided for analysis
  • No details on product diversification beyond two main products

Opportunities

  • Expansion into new markets for preventive biological products
  • Growth potential in domestic and overseas markets
  • Potential for product line expansion in biotechnology sector

Threats

  • Dependence on limited product portfolio (Rabies Vaccine and Meningococcal Vaccine)
  • Competition in the biotechnology sector
  • Regulatory challenges in vaccine production and distribution

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.